London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
C'mon Amyrt drop a little to give me an entry point here, otherwise i may need to consider breaking one of my own rules
I note with curiosity that consistently every time this stock does not move for a period it seems to fall a few pence and the rises a few % is quick succession.
Ahh yeah Bermuda..seems alot of people missed it..
Its DEFINITELY not factored into the share price..
Lack of volume is so frustrating!
Missed that the Filsuvez phase 3 results had been covered by The Times on 4th Nov
'“Something as small as finding a new bandage or a new painkiller that will work would make a difference. It doesn’t have to be the cure. It just needs to help us in some way, and that would be life changing.”
https://www.thetimes.co.uk/article/new-treatment-offers-hope-for-sufferers-of-painful-skin-condition-706vxbvmc
2 nice chunks absorbed at $13 today..
11 mins and 13 secs in - https://audioboom.com/posts/7723935-arix-bioscience-amryt-pharma-and-paul-hill-on-5-stocks-to-follow
Yawn..
Decent enough, but raising the full year revenue guidance by 6% is nothing to write home about really. They also need to do something about the operating profit.
Good Q3 results , raised FY2020 Revenue guidance:
https://www.londonstockexchange.com/news-article/AMYT/amryt-reports-record-q3-2020-results-raising-fy-2020-revenue-guidance/14745653
Bronxville,
Bronxville,
I'm not sure what you think is missing/incorrect or why you think it's shoddy and lazy. The record was updated to show that the trial is no longer recruiting and it will now just stay active. At the end of the 90 day randomised part of the trial, placebo patients are moved across to be treated with Filsuvez and then all patients can continue for up to 2 years on treatment. Of course, we won't know the impact of Covid-19 on the follow-up part of the trial but for now, as far as I can see, the clinical trial record is absolutely correct.
Not updated since April
https://www.clinicaltrials.gov/ct2/show/NCT03068780?term=amryt&draw=2&rank=1
Brronx, Agree with both your previous posts.
I guess we'll need blowout #'s next week.
Unless there's a major market correction I think we're safe enough here..
Sounded positive alright..
He presents much better that the CEO..
https://www.proactiveinvestors.co.uk/upload/SponsorFile/File/2020_10/1603979370_Amryt-Corporate-Presentation-October-29-2020-Proactive-FINAL-----Read-Only.pdf
Or whole recorded evening.Amyt on first
https://event.webinarjam.com/t/click/yyy0gsq68slxlt985fm6vkcxlpir46f5
They were first on at 1800, very good financial from from CFO
What time is Amryt on at?
There was always going to be an RNS..There has to be full exposure to the markets..
Amryt are announcing full Phase 3 trial results at a dermatology conference on Saturday..
Excellent piece here from evaluate:-
'what looks to be compelling efficacy on the important primary measure at the 45-day point'
'Add to this that an apparently narrow miss in the pain endpoint and the lack of treatments for this distressing skin disorder, and the approval case becomes even more compelling'
Https://www.evaluate.com/vantage/articles/news/snippets/amryt-data-strengthen-case-approval
Upward momentum - building.
1 million trade at £2.10.